Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy

No abstract is available for this paper.

• Publication year

  2018

• Venue

  The journal of obstetrics and gynaecology research

• Publication date

  2018-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jog.13663PMID 29727055
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endometrioid Carcinoma of the Ovary: Outcomes Compared to Serous Carcinoma After 10 Years of Follow-Up.

  2017cited by this paper
• Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum.

  2015cited by this paper
• Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum

  2015cited by this paper
• Staging classification for cancer of the ovary, fallopian tube, and peritoneum

  2014cited by this paper
• Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study

  2013cited by this paper
• Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review

  2013cited by this paper
• Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.

  2012influential reference
• Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor.

  2012influential reference
• Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis.

  2011cited by this paper
• Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery

  2011influential reference
• Rethinking ovarian cancer: recommendations for improving outcomes

  2011cited by this paper
• Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer

  2010cited by this paper
• Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum‐paclitaxel chemotherapy

  2010cited by this paper
• Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma

  2009cited by this paper
• Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies

  2008cited by this paper
• Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.

  2008cited by this paper
• Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.

  2008cited by this paper
• Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

  2007influential reference
• Ovarian cancer in younger vs older women: a population-based analysis

  2006cited by this paper
• Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.

  2005cited by this paper
• Stages III and IV Invasive Epithelial Ovarian Carcinoma in Younger Versus Older Women: What Prognostic Factors Are Important?

  2003cited by this paper
• Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

  2002influential reference
• Identification of prognostic factors in advanced epithelial ovarian carcinoma.

  2001cited by this paper
• Epithelial ovarian carcinoma in the reproductive age group

  1999cited by this paper
• Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.

  1999cited by this paper
• Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

  1996influential reference
• The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer.

  1995influential reference
• The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.

  1994cited by this paper
• The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study.

  1992influential reference
• Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.

  1991cited by this paper
• 7 The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer

  1989cited by this paper
• The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer.

  1989cited by this paper
• [Tumors of the ovary].

  1983cited by this paper

• NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer

  2022cites this paper
• Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis

  2022cites this paper
• Hubungan antara Ekspresi Heat Shock Protein-70 (HSP70) dengan Skor Risk of Ovarian Cancer Relapse (ROVAR) pada Pasien Kanker Ovarium Epitelial yang Dilakukan Operasi dan Dilanjutkan dengan Kemoterapi

  2022cites this paper
• Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.

  2021cites this paper
• Response to Multi-Line Chemotherapy in Non-Serous Epithelial Ovarian Cancer.

  2020cites this paper
• Prognostic Significance of Systematic Lymphadenectomy as Part of Primary Debulking Surgery in Patients with Ovarian Cancer

  2019influential citation